Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Provided By PR Newswire

Last update: Mar 21, 2025

Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure